ClinicalTrials.gg
RecruitingNCT06853444Updated May 16, 2025

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

A Phase 1/2 interventional study of ESG206 and ESG206 in Immune Thrombocytopenia (ITP), sponsored by Shanghai Escugen Biotechnology Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Shanghai Escugen Biotechnology Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 186 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 83 open to participants now, 93 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
79th of 168
84 · median 61
Started
2025
with 26 others
Phase 1/2
10 of 186
7 open now
Primary completion
2026-03
later than 37 of 92 live
Registered
145th of 186
by date

Among the 186 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 79th largest by planned enrollment of the 168 interventional ones that give a count, is one of 27 that started in 2025, is one of 10 in phase 1/2, reaches primary completion later than 37 of the 92 other live ones, and was the 145th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

83 of the 186 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.

Read the detailed description

Phase 1 is a dose escalation study, and Phase 2 is an extended cohort study, subjects will be treated with ESG206.

In Phase 1\&2, the study includes Screening (no more than 28 days), Treatment (14 weeks), and the post-treatment follow-up (8 weeks), for those sufferring a treatment failure, the safe follow-up will be conducted 28 days after the last dose.

And the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of ESG206 in primary ITP will be assessed in this study.

03

Conditions studied

  • Immune Thrombocytopenia (ITP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Willing and able to provide written for this trial.
    1. Male or female, age ≥ 18 years on the day of signing the informed consent form.
    1. Diagnosed with primary immune thrombocytopenia (ITP), and having received treatment of ± intravenous immunoglobulin (IVIG) in the past.
    1. At the time of the last ITP treatment, loss of response, insufficient response, no response or intolerance occurred.
    1. At screening, Count revealed \< 30 * 10\^9/L twice (with an interval of at least 24 hours between the two tests).
    1. Subjects must have adequate organ function.
    1. The World Health Organization (WHO) bleeding scale is 0-1.
    1. Fertile men and women of reproductive age must agree to use effective from the time they sign the informed consent until 180 days after the last dose of the trial drug. Women of reproductive age include premenopausal women and women within 2 years after menopause. Women who are fertile must have a pregnancy test within 7 days before the trial drug is first given and the result should be negative.

Exclusion criteria

Exclusion Criteria:

    1. Diagnosed with secondary immune thrombocytopenia, or there is evidence that the patient has a secondary cause of immune thrombocytopenia, or the patient has multiple immune cytopenias.
    1. Previously received B-cell depletion therapy (e.g., rituximab, Ianalumab, etc.).
    1. Received transfusion or whole blood transfusion, plasma exchange, or any other rescue treatment within 14 days before the first administration of the trial drug.
    1. Participated in other drug clinical studies within 4 weeks before the first administration of the investigational drug or within 5 half-lives of the investigational drug received (whichever is longer).
    1. Underwent splenectomy within 12 weeks before the first administration of the investigational drug.
    1. Received traditional Chinese medicine treatment with definite platelet-raising effects within 1 week before the first administration of the trial drug.
    1. Underwent major surgery within 4 weeks before the first administration of the investigational drug or needs to undergo major elective surgery during the study period.
    1. Diagnosed with Evans syndrome or any other cytopenia (patients with mild anemia related to bleeding or iron deficiency are eligible for inclusion in the study).
    1. Patients with current or previous life-threatening bleeding related to thrombocytopenia.
    1. Patients with concurrent coagulation disorders and/or receiving antiplatelet or anticoagulant therapy (e.g., warfarin, clopidogrel, or new oral anticoagulants), except for low-dose acetylsalicylate (≤150 mg/day).
    1. Patients with deep vein thrombosis or arterial thrombosis within 6 months before enrollment, and/or with risk factors for hereditary thrombophilia.
    1. Patients with a history of severe cardiovascular and pulmonary diseases.
    1. Patients with uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg).
    1. Patients with (HIV) infection, or active or C, or liver cirrhosis.
    1. Patients with active viral, bacterial, or other infections requiring systemic treatment during the screening period, or with a history of recurrent infections (e.g., bacterial infection with capsule). Patients with a history of tuberculosis (TB) or latent TB who have undergone anti-TB treatment may be eligible for inclusion.
    1. Patients who received live or attenuated within 4 weeks before the first administration of the investigational drug.
    1. Patients with a history of or current malignant tumors, except for cured non-melanoma skin cancer, carcinoma in situ (e.g., cervical cancer, breast cancer, bladder cancer, prostate cancer), and cancers that have been in complete remission for at least 3 years without evidence of recurrence.
    1. Patients with any severe and/or unstable pre-existing medical, mental, or other conditions that the investigator deems may interfere with the patient's efficacy, safety, , or compliance with the study procedures.
    1. Patients with known immediate or delayed reactions to monoclonal antibodies or components of the trial drug, or with a history of allergic constitution.
    1. Pregnant or lactating women.
    1. Patients who are unwilling or unable to follow the protocol procedures.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    ESG206 dose level 1

    ESG206 will be administered intravenously at dose level 1.

    Drug: ESG206

  • Experimental
    ESG206 dose level 2

    ESG206 will be administered intravenously at dose level 2.

    Drug: ESG206

  • Experimental
    ESG206 dose level 3

    ESG206 will be administered intravenously at dose level 3.

    Drug: ESG206

  • Experimental
    ESG206 dose level 4

    ESG206 will be administered intravenously at dose level 4.

    Drug: ESG206

Interventions

  • DrugESG206

    Administered via intravenous (IV) infusion

    Also known as: ESG206-2

  • DrugESG206

    Administered via intravenous (IV) infusion

  • DrugESG206

    Administered via intravenous (IV) infusion

  • DrugESG206

    Administered via intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) were defined as: Any adverse event (AE) that happens after treatment initiation, or AE that was present at time of treatment initiation but worsened after treatment initiation, or AE that was present and resolved prior to treatment and reappeared after treatment initiation after the start of study drug through 28 days after the last dose of study drug or the last post-treatment follow-up. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events.

    Time frame: Up to 24 weeks.

  2. Confirmed response rate

    Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of: Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and New immune thrombocytopenia (ITP) treatment before reaching a confirmed response.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

Secondary outcomes

  1. AUC0-inf

    Area under the serum concentration time curve (AUC) from time 0 extrapolated to infinity

    Time frame: up to Week 25

  2. Cmax

    Maximum observed plasma concentration

    Time frame: up to Week 25

  3. Tmax

    Time to maximum plasma concentration

    Time frame: up to Week 25

  4. T1/2

    Half-life

    Time frame: up to Week 25

  5. Response rate at each timepoint

    Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  6. Complete Response rate at each timepoint

    Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  7. Best Response rate at each timepoint

    Percentage of participants with Response or Complete Response in the absence of rescue treatment/new ITP treatment.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  8. Time to confirmed response

    Time from the first administration of ESG206 to the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response as defined by the primary endpoint.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  9. Time to complete response

    Time from the first administration of ESG206 to the first assessment meeting the criteria of a complete response.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  10. Time to treatment failure

    Time from the first administration until platelet count below 30 G/L, need for a rescue treatment or start of a new therapy or death.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  11. Duration of response

    Time from achievement of response to loss of response

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  12. Duration of complete response

    Time from achievement of complete response to loss of complete response.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  13. Percentage of participants receiving rescue treatment

    Assess the need of rescue treatment by percentage.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  14. Change from baseline in absolute number of CD19+ B cell counts

    Post baseline absolute number of CD19+ B cell counts compare with baseline

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  15. Change from baseline in absolute number of CD20+ B cell counts

    Post baseline absolute number of CD20+ B cell counts compare with baseline

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

  16. Incidence of anti-drug antibodies in serum (ADA assay) over time

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants assess the immunogenicity of ESG206

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Mar 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 3, 2025
StartActual
May 8, 2025
Primary completionEst.
Mar 31, 2026
CompletionEst.
Apr 30, 2027
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06853444
Lead sponsor
Shanghai Escugen Biotechnology Co., Ltd
Responsible party
Sponsor
First posted
Mar 3, 2025
Start date
May 8, 2025
Primary completion
Mar 31, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
May 16, 2025

Study contacts

Xiaoyan Xing, PhD
Contact
xingxiaoyan@escugen.com
86 21 5855 6098
Ming Hou, PhD
Contact
86 531 82169867
Ming Hou, PhD
principal investigator · Qilu Hospital of Shandong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-BAFFR Monoclonal Antibody ESG206

Start the discussion